Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02996110 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 182
- Enrollment target
NCT02996110 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 182 participants.
The verdict
NCT02996110, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 182 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- DRUG BMS-813160
- BIOLOGICAL Relatlimab
- DRUG BMS-986205
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2017-02-02 |
| Est. Completion | 2021-11-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02996110
The ClinicalTrials.gov registry entry for NCT02996110 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Nivolumab is the first listed.
NCT02996110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02996110 about?
NCT02996110 is a clinical study titled "A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma". The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer
What is the current status of trial NCT02996110?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2017-02-02. Estimated completion is 2021-11-23.
What interventions are being tested in trial NCT02996110?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), BMS-813160 (DRUG), Relatlimab (BIOLOGICAL), BMS-986205 (DRUG).
Who is sponsoring clinical trial NCT02996110?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.